财务数据和关键指标变化 - 公司第一季度实现净销售额2.8亿美元,同比增长46% [28] - 毛利润为2.3亿美元,毛利率为84%,较上年同期81%有所提升 [29] - 研发费用为1.8亿美元,较上年同期增加0.9亿美元,主要用于支持未来治疗平台的迭代 [30] - 销售、一般及管理费用为6.7亿美元,较上年同期增加0.5亿美元,主要由于裁员费用和持续的销售及营销投入 [31] - 调整后EBITDA亏损为5.1亿美元,较上年同期4.6亿美元亏损有所扩大 [32] - 经营活动现金流出为5.9亿美元,较上年同期4.8亿美元有所增加,主要由于研发投入增加 [33] - 现金及受限现金余额为12.2亿美元,较年初18亿美元有所下降 [34] 各条业务线数据和关键指标变化 - 处方用药GammaCore业务在VA/DoD医院渠道销售额增长38%,达到1.705亿美元 [15][16] - 处方用药GammaCore在商业渠道销售额增长56%,达到0.43亿美元 [16][17] - 新产品Truvaga在第一季度实现销售0.147亿美元,公司将加大营销投入 [11][12] - 新产品TAC-STIM在第一季度实现销售0.088亿美元,公司正在开发下一代TAC-STIM 2.0 [13][14] 各个市场数据和关键指标变化 - 美国以外市场销售额增长34%,达到0.41亿美元,主要来自英国NHS和日本授权费 [21] 公司战略和发展方向及行业竞争 - 公司正在开发新一代具有智能手机集成功能的治疗平台,并计划在2024年推出 [44] - 公司正在探索将GammaCore用于治疗创伤后应激障碍(PTSD)和阿片类药物成瘾(OUD)的适应症 [22][23] - 公司正在加大对Truvaga和TAC-STIM品牌的投入,看好其未来增长潜力 [11][12][13][14][39][40][45][46] 管理层对经营环境和未来前景的评论 - 管理层对公司前景表示乐观,认为各业务线都有较大增长潜力 [38][39][40][45][46] - 管理层表示将根据各业务线的表现调整营销投入,并将持续控制运营成本 [42][43] - 管理层预计2023年全年收入将达到1.4-1.5亿美元,同比增长超60% [35] 问答环节重要的提问和回答 问题1 **Unidentified Analyst 提问** 询问VA/DoD渠道的销售增长情况和未来预期 [50][51][52] **Dan Goldberger 回答** 公司正在通过开拓新客户和深耕现有客户两种方式推动VA/DoD渠道销售增长,并将继续增加销售人员投入 [53][54][55][57] 问题2 **Unidentified Analyst 提问** 询问TAC-STIM 2.0与现有产品的差异 [58][59][60] **Dan Goldberger 回答** TAC-STIM 2.0是与空军研究实验室合作开发的更加坚固耐用的新一代产品,预计将于今年夏季交付样机进行评估 [59][60] 问题3 **Unidentified Analyst 提问** 询问Truvaga产品的客户群与GammaCore是否存在差异 [62][63] **Dan Goldberger 回答** Truvaga目前主要面向年轻和高收入人群,与GammaCore在VA医院渠道的客户群存在差异,但目前销售规模较小,难以做出更多判断 [63]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-3454976 (S ...

electroCore, Inc. (NASDAQ:ECOR) Q4 2022 Results Conference Call March 8, 2023 4:30 PM ET Company Participants Nicole Jones - IR Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks Small-Cap Research Ramakanth Swayampakula - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Hello, and welcome to the electroCore Fourth Quarter and Full Year 2022 Earnings Conference Call and We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38538 electroCore, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-3454976 (I.R.S. Employer (State or other j ...

electroCore, Inc. (NASDAQ:ECOR) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Jones - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Destiny Hance - Ladenburg Thalmann John Vandermosten - Zacks Operator Greetings and welcome to the electroCore Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is bein ...

electroCore, Inc. (NASDAQ:ECOR) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the electroCore Second Quarter 2022 Earnings Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. ...

electroCore, Inc. (NASDAQ:ECOR) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks Jeremy Pearlman - Maxim Group Operator Greetings and welcome to electroCore First Quarter 2022 Earnings Conference Call. ...

electroCore, Inc. (NASDAQ:ECOR) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants Rich Cockrell - Investor Relations, CG Capital Daniel Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks Small-Cap Research Swayampakula Ramakanth - H.C. Wainwright Jeremy Pearlman - Maxim Group, LLC Operator Greetings, and welcome to electroCore F ...

electroCore, Inc. (NASDAQ:ECOR) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Rich Cockrell - CG Capital Daniel Goldberger - CEO & Director Peter Staats - Chief Medical Officer Brian Posner - CFO & Corporate Secretary Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Swayampakula Ramakanth - H.C. Wainwright & Co. John Vandermosten - Zacks Investment Research Operator Greetings, and welcome to electroCore's Third Quarter 2021 Earnings Call. [Operator In ...

electroCore, Inc. (NASDAQ:ECOR) Q2 2021 Earnings Conference Ca August 5, 2021 4:30 PM ET Company Participants Rich Cockrell - CG Capital Dan Goldberger - Chief Executive Officer Brian Posner - Chief Financial Officer Peter Staats - Chief Medical Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann John Vandermosten - Zacks SCR Operator Greetings, and welcome to the electroCore Second Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A questio ...